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overexpressing erythropoietin
Abstract
OBJECTIVE: Overexpression of erythropoietin (Epo) in mice (Epo-tg6) leads to an increase in
hematocrit and blood volume, and strongly reduces endurance upon exercise. It was the aim of this
study to characterize the mechanisms underlying the reduced cardiac performance. METHODS: Left
(LV) and right (RV) ventricular function was measured with and without norepinephrine (NE)
stimulation in 12 anaesthetized Epo-tg6 and in 13 wild-type (WT) control mice. RESULTS: There were
no differences in heart function under baseline resting conditions. Stimulation with NE (10 microl bolus
injections of 1-100 ng per mouse) in WT mice led to a dose-dependent increase in heart rate (HR), LV
developed pressure (LVDP) and rate of rise in LV pressure (LV dP/dt(max)), while LV end-diastolic
pressure (LVEDP) was unchanged. Except for HR, these parameters increased to a lesser extent in
EPO-tg6 mice. Strikingly, LVEDP strongly increased in Epo-tg6 mice after NE (up to >20 mmHg).
Eleven out of 13 Epo-tg6, but none of the WT mice died or required resuscitation after high-doses of
NE. In these cases severe diastolic dysfunction became overt since the relative myocardial relaxation
time was significantly prolonged and the duration of diastole was shortened. Moreover, the ECG
showed a marked ST segment depression as well as deep negative T-waves. The NE-induced reduction
in myocardial adenosin-triphosphate (ATP) content was more pronounced in Epo-tg6 mice after 10 min
of continuous NE infusion (50 ng/min per mouse). CONCLUSION: NE-induced stress in Epo-tg6 mice
led to acute heart failure associated with diastolic dysfunction and myocardial ischemia.
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Abstract:  
The overexpression of erythropoietin (Epo) in mice leads to an increase in hematocrit and blood 
volume. Hemodynamic characterization was done at baseline and after stimulation with 
norepinephrine (NE). Left (LV) and right (RV) ventricular function was measured in 12 
anaesthetized EPO-tg6 and in 13 wild-type (WT) littermate control mice. There were no 
differences in heart function at baseline. Stimulation with NE (10 µl i.v. bolus from 1 to 100 
ng/mouse) led in WT mice to a dose-dependent increase in heart rate (HR), LV developed 
pressure (LVDP) and maximal rate of rise in LV pressure (LVdP/dtmax), while LV end-diastolic 
pressure (LVEDP) was unchanged. Except for HR, these parameters increased to a lesser extent 
in EPO-tg6 mice. Strikingly, LVEDP strongly increased in EPO-tg6 mice after NE (up to > 20 
mmHg). 11 out of the 13 EPO-tg6 mice, but none of the WT controls died or required 
reanimation after high doses of NE. In these cases the ECG showed a marked ST segment 
depression as well as deep negative T-waves. Moreover, the NE-induced reduction in myocardial 
ATP content was more pronounced in EPO tg6 mice after 10 min of continuous NE infusion 
indicating acute heart failure had occurred due to myocardial ischemia. 
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Introduction 
The 30 kDa glycoprotein hormone Erythropoietin (Epo) is produced primarily in the kidney 
upon hypoxic stimulation and regulates the production of erythrocytes in the bone marrow. 
Recently, a transgenic mouse line (Epo-tg6) was generated that constitutively overexpresses the 
human erythropoietin cDNA in an oxygen-independent manner.1 These Epo-tg6 mice exhibit a 
more than 12-fold elevation in plasma Epo levels. This results in excessive erythrocytosis with 
hematocrit levels of 0.80 and above, which gradually develops within the first two months of 
life.2 Interestingly, the Epo transgenic mice appear to be well adapted to the high hematocrit and 
do not have arterial hypertension, despite an increase in blood viscosity and an increase in blood 
volume of 75%.2 Neither heart rate nor cardiac output differ from wild-type (WT) control 
animals.1, 2 There are also no signs of thrombosis or embolizations.3 Enhanced bioavailability of 
NO by induction and activation of the endothelial NO synthase (eNOS) seems to be part of the 
mechanism to compensate for the high hematocrit. Indeed, eNOS levels and NO-mediated 
endothelium-dependent vasorelaxation are significantly increased in the Epo-tg6 mice despite 
concomitant expression of the vasoconstrictor endothelin-1.1, 4, 5 
 
The most obvious difference regarding heart and circulatory function between the Epo transgenic 
and the wild-type control mice are enlarged hearts as well as increased preload in the 
transgenics.2 Furthermore, the Epo-tg6 mice become more easily exhausted during exercise. We 
have examined the hypothesis that the cardiovascular system is the limiting factor for the 
reduced exercise performance. We have thereby characterized heart function of Epo transgenic 
mice using ultraminiature catheter pressure transducers for catheterization of the left and right 
heart under basal resting conditions.6 Furthermore we have applied stress to the cardiovascular 
system by i.v. injection and infusion of norepinephrine (NE). 
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Materials and Methods 
Animals 
The transgenic mouse line termed TgN(PDGFBEPO)321Zbz (short: tg6) carries the human 
erythropoietin cDNA driven by the PDGF-beta promotor as described earlier.1 Hemizygous 
transgenic males were mated to wild type C57Bl/6 females. Their offspring were controlled for 
heterozygous mice and wild-type littermates, the latter serving as controls. 22 male wild type and 
23 male Epo-tg6 mice (32 ± 1.6 and 31 ± 1.4 weeks of age, respectively, and weighting 
35.0 ± 1.4 and 32.6 ± 1.0 g, respectively) were used. The animals were kept in conventional 
housing conditions and allowed to move freely in their cages with unrestricted access to standard 
rodent chow and tap water. All experimental procedures conformed to the Guide for the Care 
and Use of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996) and were approved by the appropriate State agency of 
Saxony. 
 
Hemodynamic measurements 
Heart and circulatory function was measured with ultraminiature catheter pressure transducers in 
closed-chest spontaneously breathing animals anaesthetized with thiopental sodium (Trapanal® 
80 mg/kg i.p., Byk Gulden, Konstanz, Germany) as previously described.6 Briefly, the right 
ventricular (RV) catheter (2F model SPR-612, Millar Instruments Inc., Houston, TX, USA) was 
inserted into the right jugular vein and advanced into the RV via the right atrium. After 
collection of the RV data, the left ventricular (LV) catheter (1.4F model SPR-671, Millar 
Instruments Inc., Houston, TX, USA) was placed in the right carotid artery and advanced 
upstream to the aorta and into the LV. Heart rate (HR), RVP and LVP (pressure processor 
amplifier 13-4615-52, Gould-Nicolet, Erlensee, Germany), the rates in rise and fall of ventricular 
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pressure (LV and RV dP/dt, differentiator amplifier 13-4615-71, Gould-Nicolet, Erlensee, 
Germany), and the electrocardiogram (ECG, standard limb leads with needle-electrodes, Biotach 
amplifier 20-4615-65, Gould-Nicolet, Erlensee, Germany) were recorded continuously on a PC 
at a sampling rate of 2 kHz using the PCI-6023E multifunction analogue and digital conversion 
card (National Instruments, Mönchengladbach, Germany) and DASYLab V7.00 software 
(National Instruments, Mönchengladbach, Germany). 
 
For norepinephrine (NE) application, an i.v. cannula (22 G, Vasocan® Braunüle®, B|Braun, 
Melsungen, Germany) was placed in the right jugular vein. NE was diluted appropriately in 
0.9 % NaCl, containing 100 mg/l ascorbic acid to prevent oxidation, and 1, 5, 10, 25, 50, and 100 
ng NE per mouse were injected each in a 10 µl bolus. Injections were done using a precision 
syringe (Hamilton 702N 25 µl, Hamilton Bonaduz AG, Bonaduz, Switzerland), additionally 
introducing a spacer so that the tip of the needle was placed at the tip of the cannula in the 
jugular vein. For continuous NE infusion (50 ng/min/mouse), the cannula in the jugular vein was 
replaced by an infusion catheter (PE50 tubing, Becton Dickinson, Heidelberg, Germany) and 
connected to an external pump (B|Braun, Melsungen, Germany). The pump rate was adjusted to 
10 µl/min. NE infusion was started by inserting the catheter and stopped by removing it.  
 
Myocardial ATP content 
NE or saline was infused in subgroups of WT and Epo-tg6 mice (50 ng NE/min/mouse at 
10 µl/min). After 10 min of infusion, the thorax was quickly opened, and the apical two thirds of 
the heart were rapidly cut and immediately frozen in liquid nitrogen. Tissue pieces (about 30 mg) 
were weighted and homogenized with nine parts 10 % trichloroacetic acid with an Ultra-Turrax 
T8 (IKA, Staufen, Germany). Five volumes of water saturated ether were added to the 
supernatant cleared by centrifugation, and the aqueous layer was extracted. This extraction was 
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repeated twice. The samples were diluted 1 : 5 (v/v) in Tris-EDTA buffer, and the ATP content 
was determined luminometrically using the ATP Bioluminescence Assay Kit CLS II (Roche 
Diagnostics, Boehringer Mannheim Biochemicals, Mannheim, Germany). Measurements were 
done in triplicate (1, 3 and 10 sec detection time) in two further dilutions (1:500 and 1:5000). 
ATP concentration was calculated according to the standard curve and normalized to the weight 
of tissue used. 
 
Perfusion fixation and ultrastructural Analysis 
The aorta was retrogradely cannulated, and the coronary arteries were rinsed free of blood for 
2 minutes with a modified tyrode buffer under a pressure of 100 cm H2O. This was followed by 
infusion of freshly prepared 1% formaldehyde for 10 min. Collateral vessels were dissected, and 
myocardial tissue was postfixed in 3% glutaraldehyde, then in 1% OsO4, dehydrated in alcohols 
and embedded in Epon using the Lynx Microscopy Tissue Processor (Reichert-Jung, Bensheim, 
Germany). Semithin sections were cut with the Ultracut microtome (Reichert-Jung, Bensheim, 
Germany) to a thickness of 0.5 µm, stained with toluidin blue, and analyzed with a Leica DAM 
(Leica, Bensheim, Germany) microscope. 
 
Statistical Analysis 
The data are expressed as mean ± SEM. The Mann-Whitney U-test (SigmaStat 2.0, SPSS Inc., 
Chicago, Illinois) was used for two-group comparison. One way repeated measures ANOVA 
subsequently utilizing Dunnett's multiple comparison procedure was used to test for differences 
in the dose-response to NE stimulation. A value of p< 0.05 was considered significant. 
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Results 
Hemodynamic measurements  
LV and RV function was comparable in WT and Epo-tg6 mice under baseline conditions (Table 
1). LV end-diastolic (LVEDP 6.2 mmHg) and developed pressure (98.4 mmHg) were not 
different in Epo-tg6 mice when compared with WT controls (LVEDP 5.3 mmHg, LV developed 
pressure 99.8 mmHg). The slightly reduced maximal rates in rise and fall of ventricular pressure 
(LV dP/dtmax and LV dP/dtmin, respectively) in Epo-tg6 mice did not reach the level of statistical 
significance. Additionally, the pressure-rate-product multiplied by LV dP/dtmax, indicative for 
myocardial oxygen consumption, was comparable in WT and Epo-tg6 mice. The amplitude of 
aortic pressure, however, was reduced in Epo-tg6 mice when compared with WT controls (Table 
1). 
 
The parameters of heart function increased in a dose-dependent fashion in WT mice after 
stimulation with NE (Fig. 1-3). HR, LVSP, LV dP/dtmax, and LV dP/dtmin were maximally 
elevated by 44 %, 83 %, 186 %, and 114 %, respectively, after NE application. After high-dose 
NE, LVEDP increased slightly but significantly in WT mice. Also in Epo-tg6 mice there was a 
dose-dependent response to NE stimulation, but it was significantly attenuated compared to WT 
mice. The maximum response was limited to about 75 % of that seen in WT mice with the 
exception that the increase in HR was comparable in WT and Epo-tg6 mice (Fig. 3). The 
increase in LVEDP, however, occurred in Epo-tg6 mice already after moderate NE dosages and 
was significantly pronounced when compared to WT controls. After 100 ng NE, LVEDP 
increased to 20 mmHg and above indicating severely impaired heart function. 
 
Heart function attained a new steady state at elevated levels nearly immediately after the 
initiation of continuous NE infusion (Fig. 4). All parameters returned to baseline levels within a 
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few minutes after removing the infusion catheter (Fig. 4A). As for single bolus injections, the 
increase in LVSP and both LV dP/dtmax and LV dP/dtmin after continuous NE infusion for 10 min 
was attenuated in Epo-tg6 mice, whereas there were no differences in HR (Table 1). 
Furthermore, LVEDP strongly increased in Epo-tg6 mice after 10 min NE, while it was 
unchanged in WT controls.  
 
Strikingly, 14 out of the 18 Epo-tg6 mice stimulated with NE died (Fig. 4B) or required 
reanimation after either high dose or continuous NE application (Fig. 2B). Contrarily, NE was 
well tolerated in all WT mice even after 500 ng bolus injections (data not shown). Additionally, 
there were deep ST-segment depressions and negative T-waves in the ECG (Fig. 5, ECG 1) 
under these circumstances of high-dose or continuous NE application preceding acute heart 
failure. This was highly reproducible, but occurred in none of the WT mice (Fig. 5, ECG 3). 
When the NE infusion was stopped during the periods with prominent changes in the ECG, the 
mouse could be rescued, and ECG as well as hemodynamic parameters normalized (Fig. 5, 
ECG 2).  
 
Myocardial ATP content 
Myocardial ATP content was slightly but significantly lower in Epo-tg6 mice at baseline when 
compared to WT controls (Fig. 6, left hand side). NE treatment for 10 min decreased myocardial 
ATP content in both, WT and Epo-tg6 mice. This decrease, however, was significantly 
pronounced in Epo-tg6 mice in comparison to WT mice (32.8 vs 18.6 %, respectively, Fig. 6, 
right hand side). 
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Morphology and Ultrastructure 
The most prominent difference in the myocardial tissue of Epo-tg6 mice to WT control mice 
were large euchromatic nuclei with prominent nucleoli (Fig. 7B vs. A) suggesting activated 
transcription. The myocytes of Epo-tg6 mice also showed some degree of hypertrophy 
(Fig. 7D vs. C) as well as in some cases disarray of myofibers (Fig. 7E). In addition, the hearts 
were weighted in subgroups of animals (n = 5 for Epo-tg6 mice and n = 4 for WT littermates). 
After normalization to tibia length the mean heart weight to tibia length ratio was 6.0 ± 0.2 
mg/mm (ranging from 5.3 to 6.6 mg/mm) in WT controls and 7.1 ± 0.6 mg/mm (ranging from 
5.5 to 9.3 mg/mm) in Epo-tg6 mice (p = ns). 
 
 
A. Deten et al.                                 Heart failure in erythropoietin overexpressing mice 10
Discussion 
This study demonstrates normal heart function under baseline conditions in Epo-tg6 mice 
compared with WT littermates. When, however, stress was applied to the heart and circulatory 
system by application of norepinephrine, the increase in both LV developed pressure as well as 
in contractility was impaired in the Epo-tg6 mice (Table 1). Strikingly, LVEDP increased to a 
much greater extent, and this was accompanied by a high mortality due to myocardial ischemia 
(Fig. 4B, Fig. 5, ECG 1).  
 
The Epo-tg6 mouse line was generated recently.1 It was demonstrated that the plasma levels of 
erythropoietin are about 10 – 12 fold increased in these animals resulting in a hematocrit of 0.75 
– 0.80.1, 2, 5 Interestingly, blood pressure and cardiac output were not different between WT and 
Epo-tg6 mice under resting conditions in previous studies.1, 2 Also in the present study, heart 
function was comparable in Epo-tg6 and WT mice at baseline, although the slight but significant 
reduction in the amplitude of aortic pressure may indicate an increased peripheral vascular 
resistance in Epo-tg6 mice (Table 1). The normal heart function is surprising since the 
hematocrit is a major determinant of whole blood viscosity, on which the peripheral vascular 
resistance is dependent. The tremendous increase in hematocrit, therefore, should lead to a 
reduction in blood pressure or cardiac output or both. That this does not occur under baseline 
conditions may be due to one or more compensatory mechanisms that are operative. Indeed, 
increased eNOS expression in the vessels of Epo-tg6 mice as well as increased NO 
bioavailability were observed.1 The importance of increased NO bioavailability as compensatory 
mechanism in the Epo-tg6 mice was further emphasized by the severely increased mortality in 
Epo-tg6 mice that were treated with L-NAME to inhibit endothelial NO formation.1, 4 It was, 
however, also reported that the Epo-tg6 mice show an activation of the endothelin system4, 
suggesting an impairment of regulatory vasoactive mechanisms. 
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In this study, heart and circulatory function was stimulated by the application of norepinephrine 
as physiologic transmitter of the sympathetic nervous system. There was a normal HR response, 
however, the increase in both LV pressure as well as in contractility was significantly attenuated 
in Epo-tg6 mice even after low dosages of NE (Fig. 1, 2 and 3). After higher NE concentrations 
or continuous infusion, also LVEDP markedly increased and, most strikingly, about 80 % of the 
Epo-tg6 but none of the WT mice died (Fig. 4B) or required reanimation (Fig. 2B). These 
complications typically occurred after 5 to 10 min of continuous NE infusion. This is in perfect 
accordance with a previous report on reduced endurance of Epo-tg6 mice in treadmill test in 
which the Epo-tg6 mice suffered from exhaustion after 6 min.2 The deep ST-segment 
depressions and negative T-waves in the ECG in our study preceding acute heart failure (Fig. 5, 
ECG 1) are typical signs of myocardial ischemia. It is, therefore, reasonable to suggest that the 
acute heart failure is triggered by an impairment of the balance of myocardial oxygen demand 
and delivery. Indeed, the pressure-rate-product multiplied by LV dP/dtmax, indicative for 
myocardial oxygen consumption, reached maximum in the Epo-tg6 mice already after 25 to 50 
ng NE (Fig. 3), while it still increased in WT mice after 500 ng NE (not shown). The suggestion 
of myocardial ischemia is further strengthened by the more pronounced decrease in myocardial 
ATP content in the Epo-tg6 mice after 10 min of NE infusion compared to their WT littermates 
(Fig. 6). 
 
The mechanism by which NE induces myocardial ischemia in the Epo-tg6 mice may be that the 
coronary blood vessels of the Epo-tg6 mice are dilated when compared to WT controls and that 
this may be nearly maximal. Therefore, there may be no further dilatation that would be 
necessary to meet the increased requirements of the myocardium induced by NE. This situation 
gets even worse since the hearts of the Epo-tg6 mice are dilated 1, 2 resulting in an increased LV 
wall tension. Therefore, the relative myocardial oxygen consumption might be increased per se 
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as well as the diastolic coronary blood supply impaired. Any further stimulation obviously 
exceeds the capacity of compensatory mechanisms. Finally, the hearts of the Epo-tg6 mice are 
also hypertrophied (Fig. 7).2 The resulting increase in the distances for oxygen diffusion may 
also impair oxygen delivery especially under stress conditions. 
 
A limited number of studies on isolated erythrocytosis has been carried out in dogs, rats and 
mice so far. Despite differences between species or in the experimental setup, it is obvious that 
the mechanisms to compensate for the high hematocrit are time-dependent. In an early study in 
dogs, cardiac output was reduced by about 50 % when hematocrit was raised to a mean of 47 % 
above normal by bleeding and reinjecting freshly spun red blood cells within only 3 min.7 In 
contrast, no cardiovascular alterations were observed in rats when hematocrit was increased to 
0.63 over 3 weeks by the administration of 500 units Epo thrice weekly.8 Erythrocytosis 
developed gradually also in Epo-tg6 mice over several weeks while growing up.2 Although the 
hematocrit increased to much higher values, the gradual increase probably enabled the 
cardiovascular system to adapt. In the vasculature these compensatory mechanisms include 
enhanced vasodilatation via increased bioavailability of NO.1, 4, 5 This may be induced by Epo 
directly9, 10 or as a result of the increased shear stress. The cardiac alterations are most likely 
secondary to increased blood volume (preload) and/or increased peripheral vascular resistance 
(afterload) thereby including cardiac dilatation as well as hypertrophy. However, no cardiac 
hypertrophy was observed in rats with a hematocrit of 0.63 by Epo administration.8, 11 In 
contrast, moderate hypertrophy of the right ventricle or of both the right and left ventricle 
occurred in mice after intraperitoneal injection of packed red cells into mice resulting in a 
hematocrit of 0.67 to 0.80.12, 13 
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The increase in hematocrit is accompanied by an increase in blood volume.2 This, in turn, leads 
to ventricular dilatation and adaptive hypertrophy.1, 2 Indeed, the hearts of Epo-tg6 mice looked 
tremendously enlarged when the thorax was opened. However, as soon as the heart is emptied of 
blood, the size apparently normalized. This dilatation was sufficient to induce disarray of 
myofibers as typical sign of dilated cardiomyopathy (Fig. 7E). Additionally, the myocytes of the 
hearts of Epo-tg6 mice were hypertrophied (Fig. 7D). The hypertrophy of the heart as measured 
by heart weight to tibia length ratio, however, largely varied in this study and was not 
statistically significant in the small subgroup analyzed. The measured heart weights of 114 ± 4 
mg and 135 ± 11 mg for WT and Epo-tg6 mice, respectively, were very close to the values in a 
recent report of about 130 mg and 140 mg (n = 8, p = 0.057) for WT and Epo-tg6 mice, 
respectively.2 In this previous study also 30 % hypertrophy of both the right and left ventricular 
free wall, but not of the intraventricular septum was noted. The variation in heart weight might 
be attributed to the degree of cell loss, which occurs in dilative cardiomyopathy. Presuming that 
the amplitude of aortic pressure reflects the peripheral vascular resistance to some degree, it is of 
interest to note that there was a relatively strong negative correlation between the amplitude of 
aortic pressure and heart weight (r = -0.91, p < 0.001). Therefore, one might suggest that in 
addition to the increase in preload due to volume overload by increased blood volume also an 
increase in afterload due to high blood viscosity and peripheral vascular resistance contributes to 
the development of cardiac hypertrophy. This component of compensatory mechanisms may 
vary depending on the activation of the endothelial NO synthase and the concomitant expression 
of the vasoconstrictor endothelin-1.1, 4, 5 
 
The main difference between the Epo-tg6 mice and the usual pathophysiological conditions of 
elevated hematocrit is that it is hypoxia-independent. Interestingly, hematocrit levels up to 0.90 
have been reported in Peruvian high altitude dwellers who were also normotensive.14 The 
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relationship between hematocrit and blood pressure, however, remain unclear. Both aspects may 
be associated,15, 16 but erythrocytosis does not necessarily lead to hypertension.17, 18 Beside 
hypoxia, most erythrocytotic conditions involve all three blood cell lines (polycythemia vera) or 
are secondary to others disorders (i.e., cyanotic congenital heart disease, malignancies or 
Cushing disease) to which changes in blood pressure have to be attributed. That the 
erythrocytosis in the Epo-tg6 mice occurs isolated from other cell lines or hormones may, in part, 
also explain why there is no sign of thrombosis or embolizations. Obviously there are additional 
protective mechanisms regarding coagulation.5  
 
In summary, the cardiovascular system seems to be the limiting factor for the response of the 
heart to NE and for the reduced endurance in Epo-tg6 mice2 since there is a severe dysregulation 
of coronary blood flow resulting in critical myocardial ischemia. In combination with the dilative 
and hypertrophic cardiomyopathy secondary to the increases in both preload and afterload, the 
stress-induced coronary insufficiency may be added to the complex cardiac phenotype of the 
Epo-tg6 mice. Thus, this animal model exhibits some features which reflect major aspects of the 
pathophysiological situation in patients.  
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Figure legends 
 
Fig. 1: Effect of low dose norepinephrine application 
Original recordings of LVP (upper tracing), LV dP/dt (middle tracing) and HR (lower tracing) in 
a WT (A) and an Epo-tg6 mouse (B). Norepinephrine was injected intravenously in a bolus of 10 
µl at the times and dosages indicated. 
 
Fig. 2: Effect of high dose norepinephrine application 
Original recordings of LVP (upper tracing), LV dP/dt (middle tracing) and HR (lower tracing) in 
a WT (A) and an Epo-tg6 mouse (B). Norepinephrine was injected intravenously in a bolus of 10 
µl at the times and dosages as indicated. 
 
Fig. 3: Summery of hemodynamic data after norepinephrine bolus injections 
Dose-dependent changes in HR (A), triple product of LVSP*HR*LV dP/dtmax (B), LVSP (C), 
LVEDP (D), LV dP/dtmax (E) and – LV dP/dtmin (F) in WT (open circles) and Epo-tg6 mice 
(closed circles) after norepinephrine bolus injections as indicated (ng/mouse). Data are 
mean ± SEM; n = 12 for WT and n = 13 for Epo-tg6 mice except n = 9 for Epo-tg6 after 100 ng 
NE; † p < 0.05 vs. baseline; * p < 0.05 vs. WT (same treatment). 
 
Fig. 4: Effect of continuous Norepinephrine application 
Original recordings of LVP (upper tracing), LV dP/dt (middle tracing) and HR (lower tracing) in 
a WT (A) and two Epo-tg6 mice (B and C). Norepinephrine infusion (10 µl/min of 5 ng/µl) was 
started and stopped as indicated by the arrows at the bottom of the panels. At the top of the upper 
and the lower panels the time points are indicated at which ECG measurements were taken, They 
are reproduced in Fig. 5. 
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Fig. 5: Myocardial ischemia under norepinephrine infusion 
Original recordings of LVP (upper tracing), LV dP/dt (middle tracing) and ECG (standard limb 
lead I, lower tracing) in an Epo-tg6 mouse (ECG 1 and ECG 2) and a WT mouse (ECG 3). The 
tracings were taken from the animals of Fig. 4 at the time points indicated with a higher 
resolution. 
 
Fig. 6: Myocardial ATP content after 10 min of norepinephrine infusion 
Myocardial ATP content was determined luminometrically in WT (light columns) and Epo-tg6 
mice (dark columns) after 10 min of saline (CTRL) or norepinephrine (NE) infusion. Data are 
mean ± SEM; n = 5 per group except for n = 3 for Epo-tg6 CTRL; † p < 0.05 vs. CTRL; * 
p < 0.05 vs. WT (same treatment). 
 
Fig. 7: Ultrastructural analysis of hearts from wild-type and erythropoietin overexpressing mice 
Original microphotographs of longitudinal (A, B and E) and cross sections (C and D) of WT (A 
and C) and Epo-tg6 mice (B, D and E) demonstrating large euchromatic nuclei with prominent 
nucleoli (B), enlarged myocytes (D) and disarray of myofibers (E). Scale bar provided in A 
represents 10 µm, same magnification for all microphotographs. 
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Tab 1 Heart function at baseline and after norepinephrine-infusion for 10 min (50 ng/min)
WT  Epo-tg6
HR [bpm]   434 ± 11   441 ± 15
LVSP [mmHg] 105.2 ± 4.5 104.5 ± 4.1
LVEDP [mmHg]     5.3 ± 0.3     6.2 ± 0.4
LV dP /dt max [mmHg/s]   6523 ± 416   5741 ± 365
LV dP /dt min [mmHg/s]  -6368 ± 453 -5805 ± 366
LVSP*HR*LV dP /dt max [103 mmHg2/s2]   4792 ± 592  4560 ± 467
DAP [mmHg]   77.9 ± 3.5  81.9 ± 3.5
Ampl [mmHg]   26.6 ± 1.3     22.1 ± 0.9 *
RVSP [mmHg]    24.9 ± 0.8    26.9 ± 1.1
RVEDP [mmHg]      5.2 ± 0.2      4.6 ± 0.4
RV dP /dt max [mmHg/s]  1171 ± 90  1273 ± 70
RV dP /dt min [mmHg/s] -1051 ± 70 -1144 ± 44
RVSP*HR*RV dP /dt max [103 mmHg2/s2]    197 ± 23    243 ± 27
HR [bpm]    675 ± 23 † 650 ± 17 †
LVSP [mmHg]  141.2 ± 3.1 † 119.9 ± 5.8 †*
LVEDP [mmHg]   4.9 ± 0.2   14.9 ± 1.3 †*
LV dP /dt max [mmHg/s]  18345 ± 741 † 10892 ± 912 †*
LV dP /dt min [mmHg/s] -11635 ± 542 †  -7656 ± 721 †*
LVSP*HR*LV dP /dt max [103 mmHg2/s2]    29070 ± 2147 †   15465 ± 1938 †*
Data are mean ± SEM; n = 12 for WT, n = 13 for Epo-tg6 at baseline and n = 5 for WT after NE; 
* p < 0.05 vs WT; † p < 0.05 vs baseline
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